.png)
Rgenta Therapeutics, Massachusetts, United States
Sam Hasson is currently a Senior Director at Rgenta Therapeutics (Woburn, Massachusetts). His current research aims to develop small molecular modulators of RNA processing, expanding on his previous drug discovery efforts in therapeutic manipulation of pre-mRNA splicing. Before transitioning to Rgenta, Sam has had the opportunity to engage in modalities including AAV-based gene therapy (Voyager Therapeutics), antibody-based neuro-immune modulation (Amgen), and small-molecule neuro-immune modulation, all for unmet medical needs in the CNS. He has led groups that focus on the deconvolution of human disease genetics for drug target selection, employing genome editing technologies to enable this process. As a postdoc, Sam trained with Richard Youle and Jim Inglese at the National Institutes of Health where he first realized the potential of genome editing in drug discovery.
Disclosure information not submitted.
Genome Editing Applications in Drug Discovery and Target Validation
Saturday, February 3, 2024
8:30 AM – 4:30 PM EST